GENMAB

Genmab’s modest share‑capital lift and unchanged board fees focus on RSU‑based incentives and heightened transparency, driving a 2,900 DKK target‑price upgrade.

Low short interest in Genmab A/S signals limited bearish sentiment, yet strong pipeline, safety, and regulatory traction make it an attractive biotech for investors.

Genmab’s modest 38 m DKK capital raise via employee warrants shows disciplined growth, preserves shareholder value, and fuels its oncology pipeline.

Genmab’s 12% revenue surge and promising Phase‑III data could boost its market value, but investors weigh supply‑chain risks and payer‑model shifts.

Genmab’s earnings lift European biotech, boosting the Stoxx 600 and spotlighting its antibody pipeline, market‑access strategy, and future growth prospects.

Genmab’s Q2 earnings exceed expectations, driven by Darzalex royalties and rising Epkinly sales, prompting higher full‑year guidance and a strong pipeline outlook.

Genmab/AbbVie’s phase‑3 EPCORE DLBCL‑1 study shows epcoritamab improves PFS and ORR, yet falls short of US OS approval—implications for patients, payers, and Genmab’s future strategy.

Genmab and AbbVie reveal that the U.S. phase‑3 EPCORE DLBCL‑1 trial of epcoritamab failed to improve overall survival in relapsed/refractory DLBCL, raising regulatory questions.

Genmab and Merus launch bispecific INCA33890, targeting TGFβR2 and PD‑1 to turn “cold” MSS colorectal cancers “hot,” promising a new immunotherapy option.

Genmab’s Phase 3 EPCORE DLBCL‑4 trial shows epcoritamab + lenalidomide cuts progression risk by ~60 % in relapsed/refractory DLBCL, with a manageable safety profile and potential for broader use.